---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-108847"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:21:58.825213+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q3 net loss $6.0M, cash $42.7M; plans OLC NDA resubmission by year-end 2025

## Summary
- Net loss of $6.0M for Q3 2025 vs $4.1M in Q3 2024; cash $42.7M as of Sept 30, 2025, with runway into 2027.
- On track to resubmit NDA for oxylanthanum carbonate (OLC) by year-end 2025 after positive FDA Type A meeting; potential PDUFA in H1 2026.
- Presented OLC data at ASN Kidney Week showing 7x reduction in pill volume and 2x reduction in pill count vs current binders.
- R&D expenses flat at $3.0M; G&A increased to $4.4M from $3.2M due to higher labor and consulting costs.

## SEC filing metadata
- accession: 0001213900-25-108847
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390025108847/0001213900-25-108847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390025108847/ea0265227-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-108847
- JSON: https://secwatch.observer/filing/0001213900-25-108847.json
- Plain text: https://secwatch.observer/filing/0001213900-25-108847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.